548 related articles for article (PubMed ID: 27578767)
1. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
[TBL] [Abstract][Full Text] [Related]
2. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR
J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683
[TBL] [Abstract][Full Text] [Related]
3. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.
Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J
J Psychopharmacol; 2023 Jan; 37(1):49-60. PubMed ID: 36515370
[TBL] [Abstract][Full Text] [Related]
4. Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature.
Honyiglo E; Franchi A; Cartiser N; Bottinelli C; Advenier AS; Bévalot F; Fanton L
J Forensic Sci; 2019 Jul; 64(4):1266-1270. PubMed ID: 30548541
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin--summary of knowledge and new perspectives.
Tylš F; Páleníček T; Horáček J
Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
[TBL] [Abstract][Full Text] [Related]
6. [Automutilation after consumption of hallucinogenic mushrooms].
Attema-de Jonge ME; Portier CB; Franssen EJ
Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2869-72. PubMed ID: 18257429
[TBL] [Abstract][Full Text] [Related]
7. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Studerus E; Kometer M; Hasler F; Vollenweider FX
J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
[TBL] [Abstract][Full Text] [Related]
8. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Griffiths RR; Richards WA; McCann U; Jesse R
Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
[TBL] [Abstract][Full Text] [Related]
9. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
[TBL] [Abstract][Full Text] [Related]
10. Psilocybin: Good Trip or Bad Trip.
Sellers EM
Clin Pharmacol Ther; 2017 Oct; 102(4):580-584. PubMed ID: 28548221
[TBL] [Abstract][Full Text] [Related]
11. Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use.
Roberts CA; Osborne-Miller I; Cole J; Gage SH; Christiansen P
J Psychopharmacol; 2020 Sep; 34(9):999-1007. PubMed ID: 32674668
[TBL] [Abstract][Full Text] [Related]
12. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
13. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
[TBL] [Abstract][Full Text] [Related]
14. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
15. DARK Classics in Chemical Neuroscience: Psilocybin.
Geiger HA; Wurst MG; Daniels RN
ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
[TBL] [Abstract][Full Text] [Related]
16. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
17. Neuroticism is associated with challenging experiences with psilocybin mushrooms.
Barrett FS; Johnson MW; Griffiths RR
Pers Individ Dif; 2017 Oct; 117():155-160. PubMed ID: 28781400
[TBL] [Abstract][Full Text] [Related]
18. Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett FS; Doss MK; Sepeda ND; Pekar JJ; Griffiths RR
Sci Rep; 2020 Feb; 10(1):2214. PubMed ID: 32042038
[TBL] [Abstract][Full Text] [Related]
19. Peak experiences of psilocybin users and non-users.
Cummins C; Lyke J
J Psychoactive Drugs; 2013; 45(2):189-94. PubMed ID: 23909006
[TBL] [Abstract][Full Text] [Related]
20. [Hallucinogenic mushrooms].
Reingardiene D; Vilcinskaite J; Lazauskas R
Medicina (Kaunas); 2005; 41(12):1067-70. PubMed ID: 16401965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
